Aug 2026· Bioinformatics· Vol 42· 0 citations· 32 references
Medicine
TL;DR
A two-stage contrastive learning framework integrating drug structures, protein sequences, and Cell Painting morphological profiles into a unified embedding space, which reveals pathway-specific morphological signatures associated with drug targets, providing biologically interpretable insights into drug mechanisms.
Abstract
Abstract Motivation Accurate prediction of drug-target interactions (DTIs) is fundamental to drug discovery and mechanistic understanding. While deep learning has advanced computational DTI prediction, most existing methods rely primarily on molecular structural representations, including drug structures and protein sequences, while overlooking cellular phenotypes that reflect downstream biological effects. Cell Painting enables high-content morphological profiling that captures systems-level responses to chemical and genetic perturbations but remains underutilized in DTI modeling. Integrating molecular information with cellular phenotypes offers an opportunity to improve both predictive performance and biological interpretability. Results We propose a two-stage contrastive learning framework integrating drug structures, protein sequences, and Cell Painting morphological profiles into a unified embedding space. Stage 1 learns modality-specific representations independently from structure-based and image-based data; Stage 2 aligns these via multi-positive contrastive learning to bridge molecular structural information with cellular phenotypes. Cross-modal retrieval achieves median Recall@10 values of 0.77 (random split) and 0.33 (scaffold split), outperforming bilinear and random baselines. In external DTI prediction on the BIOSNAP dataset, our model achieves an AUC of 0.92 with image-based representations and 0.90 under structure-only settings, surpassing existing methods. Model interpretation via integrated gradients reveals pathway-specific morphological signatures associated with drug targets, providing biologically interpretable insights into drug mechanisms. Availability https://github.com/YJRubyLai/Unified-DTI
PMRD separates mechanism-consistent factors from modality-specific information and constructs a consensus response domain across three modalities and combines complementary representations through reliability-aware multiview retrieval and supports PMRD as an effective framework for mechanism-aware multimodal drug repre...
Jintao Huang, Lu Leng, Ziyuan Yang· arXiv.org· 0 citations
PhenMol disentangles molecular and cellular representations into shared and private components, enabling phenotype-guided alignment while preserving chemical structures through a dedicated molecular branch, and improves molecular property prediction across 270 bioactivity tasks, molecule--phenotype retrieval, and clini...
Xuan Lin, Jingyu Sheng, Tengfei Ma et al.· 0 citations
This review provides a systematic overview of recent advances in SSL-based molecular property prediction and analyzes how multimodal molecular representation learning by integrating sequence, graph, three-dimensional structure, and textual information can improve the quality and expressiveness of molecular representati...
Shuning Yang, Lei Deng· Journal of Chemical Informat...· 0 citations
The DRL-DSP is proposed, a novel dual representation learning framework designed to enhance drug synergy prediction by integrating molecular-level features from SMILES sequences with graph-level relational information from reconstructed molecular networks.
Juanzi Zhou, Xiaoliang Yang, Yin Zhang et al.· Intelligent Data Analysis· 0 citations
The proposed PCBERT-GAT-DFFNN-DTA model, a three-stage deep cross-modal representation fusion framework for accurate DTA prediction, achieves significant improvements in R2 scores across all datasets, demonstrating its effectiveness in learning complex drug protein interactions for reliable DTA prediction.
Essmily Simon, Sanjay S. Bankapur· Analytical Biochemistry· 0 citations
Abstract Motivation Accurate prediction of synergistic drug combinations can accelerate anticancer combination discovery. Existing methods inadequately model higher order drug–drug–cell-line interactions and drug–disease associations and remain sensitive to sparse and noisy multiomics data, limiting generalization to u...
Yunxia Gu, Xindi Huang, Lifen Shi et al.· Bioinform.· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.